Celgene posts upbeat Q1 results on multiple myeloma drug

[anonymous]

Celgene reported better-than-expected first quarter results, as its flagship drug for multiple myeloma continued to increase in new and repeat prescriptions and longer average duration of use.

Revenue continued to be benefited from the company’s key growth driver Revlimid, which was approved for several cancer indications including multiple myeloma. Revlimid has risen 19% driven by market share gains in key markets and longer treatment duration.

Infographics and rest of the article can be found at https://news.alphastreet.com/celgene-posts-upbeat-q1-on-multiple-myeloma-drug/

 

[anonymous]

Ok, so now what??

 

[anonymous]

get the stock to 150.00!

 

[anonymous]

Good luck with that Kool aid drinker

 

[anonymous]

Good luck with that Kool aid drinker

i responded to the previous post .
I don’t work at Celgene, just hold way to much stock that is underwater and you shit heads need to find a way to fix the mess you made. By the way there are multiple investigations of fraud. Looks like the only way you can make the numbers is by raising prices! Good luck with that strategy.

 

[anonymous]

Why is Wall Street so hard on Celgene? Other companies not as much...

 

[anonymous]

i responded to the previous post .
I don’t work at Celgene, just hold way to much stock that is underwater and you shit heads need to find a way to fix the mess you made. By the way there are multiple investigations of fraud. Looks like the only way you can make the numbers is by raising prices! Good luck with that strategy.

Hi, what are the investigations on fraud, any link to that information ?

 

[anonymous]

not sure about the fraud but google “ class action lawsuit Celgene”